Picture of HLB BioStep Co logo

278650 HLB BioStep Co Income Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for HLB BioStep Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
R2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue37,23746,04058,52064,40386,277
Cost of Revenue
Gross Profit26,80133,67143,13342,05653,400
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses31,83739,30749,67550,42481,212
Operating Profit5,4016,7338,84513,9795,065
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes4,4495,3759,47112,827-2,345
Provision for Income Taxes
Net Income After Taxes3,8564,5548,58911,532-2,870
Minority Interest
Net Income Before Extraordinary Items
Net Income3,5544,1958,30211,031-2,995
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income3,6364,1958,30211,031-2,995
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS69.674.1120107-30
Dividends per Share